NasdaqCM:CUENasdaqCM:CUEBiotechsCue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, AnywayMay 12, 2022David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
NasdaqCM:ATOSNasdaqCM:ATOSBiotechsCompanies Like Atossa Therapeutics (NASDAQ:ATOS) Are In A Position To Invest In GrowthMay 12, 2022Just because a business does not make any money, does not mean that the stock will go down. For example, although...
NasdaqGS:YMABNasdaqGS:YMABBiotechsIs Y-mAbs Therapeutics (NASDAQ:YMAB) In A Good Position To Invest In Growth?May 12, 2022There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
NasdaqGM:MNOVNasdaqGM:MNOVBiotechsInvestors three-year losses grow to 82% as the stock sheds US$16m this past weekMay 12, 2022As an investor, mistakes are inevitable. But really bad investments should be rare. So take a moment to sympathize with...
NasdaqGM:ADVMNasdaqGM:ADVMBiotechsWe Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth CarefullyMay 12, 2022Just because a business does not make any money, does not mean that the stock will go down. For example, although...
NasdaqCM:PNTNasdaqCM:PNTBiotechsPOINT Biopharma Global Inc.'s (NASDAQ:PNT) market cap dropped US$269m last week; individual investors who hold 40% were hit as were institutionsMay 12, 2022A look at the shareholders of POINT Biopharma Global Inc. ( NASDAQ:PNT ) can tell us which group is most powerful. And...
NasdaqCM:NBSENasdaqCM:NBSEBiotechsWe Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth CarefullyMay 12, 2022We can readily understand why investors are attracted to unprofitable companies. For example, although...
NasdaqGM:ACETNasdaqGM:ACETBiotechsAdicet Bio (NASDAQ:ACET shareholders incur further losses as stock declines 31% this week, taking one-year losses to 17%May 12, 2022Investors can approximate the average market return by buying an index fund. While individual stocks can be big...
NasdaqGS:JNCENasdaqGS:JNCEBiotechsAfter a 18% dip, insiders are undoubtedly glad they sold Jounce Therapeutics, Inc. (NASDAQ:JNCE)May 12, 2022By selling US$469k worth of Jounce Therapeutics, Inc. ( NASDAQ:JNCE ) stock at an average sell price of US$6.88 over...